50 results about "Bone marrow transplants" patented technology

The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.

The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies / immunotherapies and / or radiation therapies.

The invention discloses an acetylcysteine gargle for treating dental ulcers, and a preparation method thereof. The preparation method comprises the following steps: cooling a small amount of purified water by mass percent; adding the acetylcysteine and then stirring and mixing; under a stirring action, regulating the pH value until the acetylcysteine is dissolved; adding a solution stabilizer, a corrigent and a corrosion remover and mixing; adding poloxamer and then stirring till dissolving; statically placing an obtained mixture; filtering the mixture; and adding the water to a filtrate, thereby obtaining the acetylcysteine gargle. The acetylcysteine gargle prepared by using the method has the functions of quickly relieving pain and preventing / treating the ulcers, and especially has the medicinal efficacy of inhibiting the continuous ulcer expansion and promoting the ulcer wound healing for patients accepting radiotherapy, chemotherapy and bone marrow transplantation. The method provided by the invention has the advantages of simple preparation process and easiness in industrial scale production realization. The acetylcysteine gargle provided by the invention has the advantages of high stability, single and clear active ingredients and good quality controllability, thereby enriching the drug category for adjuvant therapy of clinical cancer. Therefore, a good selection for the nursing service of the patients accepting the radiotherapy is provided.

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.

The invention discloses a method for analyzing mixed sample DNA. The mixed sample DNA is analyzed with a method combining INDEL with Microhaplotypes; in other words, father source or mother source DNAof an individual is sorted through differential amplification of the INDEL, and then individual distinguishing is conducted through the Microhaplotypes on DNA molecules; the method is named a DIP-Microhaplotypes method. The method has the advantages that analysis of a mixed DNA sample of two samples and detection of mixed stain sensitivity mainly depend on the INDEL, following detection of SNP isrelated to a detection means, and mixed stains can be successfully analyzed and used for excluding or confirming the individual; an INDEL-SNP primer has species specificity and is suitable for forensic medicine detection; the method is possibly used for monitoring transplant ingredients in peripheral blood after a bone marrow transplantation operation or other organ transplantation operations; the method is possibly used for all cases where individuals need to be distinguished when the mixed sample is involved.

A method of inducing tolerance to a transplant transplanted from a donor to a subject is disclosed. The method comprises (a) restricting outflow of a fluid from a portion of the circulatory system of the subject; and (b) administering a dose of bone marrow cells derived from the donor to a body part delimiting said portion of the circulatory system, prior to, concomitantly with or following transplantation of the transplant, thereby inducing tolerance to the transplant in the subject.

A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and / or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation / implantation thereof. The composition and methods of the invention enable restoring and / or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and / or their products, genetic conditions resulting in abnormal stem cells and / or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and / or MBM.

The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

The present invention relates to methods of synthesizing 18F-FMAU. In particular, 18F-FMAU is synthesized using one-pot reaction conditions in the presence of Friedel-Crafts catalysts. The one-pot reaction conditions are incorporated into a fully automated cGMP-compliant radiosynthesis module, which results in a reduction in synthesis time and simplifies reaction conditions. The one-pot reaction conditions are also suitable for the production of 5-substituted thymidine or cytidine analogs. The products from the one-pot reaction (e.g. the labeled thymidine or cytidine analogs) can be used as probes for imaging tumor proliferative activity. More specifically, these [18F]-labeled thymidine or cytidine analogs can be used as a PET tracer for certain medical conditions, including, but not limited to, cancer disease, autoimmunity inflammation, and bone marrow transplant.

Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.

The present invention provides a compound represented by the following formula (I):wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.

A recombinant human diad stem cell factor (rhdSCF) used for radiotherapy, chemicotherapy and recreating and restoring the hematognesis and immune function after bone marrow transplantation is disclosed. It sequentially contains amino acid codons No1-165 of human SCF, 12 amino acid linker peptides, codons No1-145 of human SCF and DNA fragment of termination codon. Its advantage is high specific activity.

A Chinese medicine composition for treating leukemia bone marrow transplant failure complicated by brain stem stroke after chemotherapy, wherein the composition is prepared by the following steps: (A) providing a mixture; (B) mixing the mixture with water and heating the mixture to obtain a crude extract; and (C) filtering the crude extract to remove a residue and obtain a liquid extract; wherein the mixture comprises Fructus corni, Rehmannia glutinosa, Rhizoma dioscoreae, Angelica sinensis, Cortex eucommiae, Semen cuscutae, Fructus lycii, Cinnamomum cassia, Radix aconiti lateralis preparata, Rhizoma zingiberis, Poria, Cortex phellodendri, Radix achyranthis bidentatae, and Atractylodes lancea.

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.